Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.
Australia
COVID-19
SARS-CoV-2
seroprevalence
serosurvey
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
23
08
2021
accepted:
26
01
2022
entrez:
16
2
2022
pubmed:
17
2
2022
medline:
17
2
2022
Statut:
epublish
Résumé
As of mid-2021, Australia's only nationwide coronavirus disease 2019 (COVID-19) epidemic occurred in the first 6 months of the pandemic. Subsequently, there has been limited transmission in most states and territories. Understanding community spread during the first wave was hampered by initial limitations on testing and surveillance. To characterize the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody seroprevalence generated during this time, we undertook Australia's largest national SARS-CoV-2 serosurvey. Between June 19 and August 6, 2020, residual specimens were sampled from people undergoing general pathology testing (all ages), women attending antenatal screening (20-39 years), and blood donors (20-69 years) based on the Australian population's age and geographic distributions. Specimens were tested by Wantai total SARS-CoV-2-antibody assay. Seroprevalence estimates adjusted for test performance were produced. The SARS-CoV-2 antibody-positive specimens were characterized with microneutralization assays. Of 11 317 specimens (5132 general pathology; 2972 antenatal; 3213 blood-donors), 71 were positive for SARS-CoV-2-specific antibodies. Seroprevalence estimates were 0.47% (95% credible interval [CrI], 0.04%-0.89%), 0.25% (CrI, 0.03%-0.54%), and 0.23% (CrI, 0.04%-0.54%), respectively. No seropositive specimens had neutralizing antibodies. Australia's seroprevalence was extremely low (<0.5%) after the only national COVID-19 wave thus far. These data and the subsequent limited community transmission highlight the population's naivety to SARS-CoV-2 and the urgency of increasing vaccine-derived protection.
Sections du résumé
BACKGROUND
BACKGROUND
As of mid-2021, Australia's only nationwide coronavirus disease 2019 (COVID-19) epidemic occurred in the first 6 months of the pandemic. Subsequently, there has been limited transmission in most states and territories. Understanding community spread during the first wave was hampered by initial limitations on testing and surveillance. To characterize the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody seroprevalence generated during this time, we undertook Australia's largest national SARS-CoV-2 serosurvey.
METHODS
METHODS
Between June 19 and August 6, 2020, residual specimens were sampled from people undergoing general pathology testing (all ages), women attending antenatal screening (20-39 years), and blood donors (20-69 years) based on the Australian population's age and geographic distributions. Specimens were tested by Wantai total SARS-CoV-2-antibody assay. Seroprevalence estimates adjusted for test performance were produced. The SARS-CoV-2 antibody-positive specimens were characterized with microneutralization assays.
RESULTS
RESULTS
Of 11 317 specimens (5132 general pathology; 2972 antenatal; 3213 blood-donors), 71 were positive for SARS-CoV-2-specific antibodies. Seroprevalence estimates were 0.47% (95% credible interval [CrI], 0.04%-0.89%), 0.25% (CrI, 0.03%-0.54%), and 0.23% (CrI, 0.04%-0.54%), respectively. No seropositive specimens had neutralizing antibodies.
CONCLUSIONS
CONCLUSIONS
Australia's seroprevalence was extremely low (<0.5%) after the only national COVID-19 wave thus far. These data and the subsequent limited community transmission highlight the population's naivety to SARS-CoV-2 and the urgency of increasing vaccine-derived protection.
Identifiants
pubmed: 35169588
doi: 10.1093/ofid/ofac002
pii: ofac002
pmc: PMC8842318
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofac002Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
N S W Public Health Bull. 2003 Apr-May;14(4-5):90-3
pubmed: 12806408
Lancet Infect Dis. 2021 Apr;21(4):e75-e76
pubmed: 32763195
Sci Immunol. 2020 Dec 7;5(54):
pubmed: 33288645
JAMA Pediatr. 2021 Feb 1;175(2):143-156
pubmed: 32975552
Nat Hum Behav. 2021 Jul;5(7):947-953
pubmed: 33972767
Open Forum Infect Dis. 2021 May 10;8(7):ofab239
pubmed: 34258311
J Infect. 2021 Feb;82(2):282-327
pubmed: 32956726
PLoS One. 2020 Dec 31;15(12):e0244126
pubmed: 33382764
Ann Intern Med. 2021 May;174(5):655-662
pubmed: 33481642
Sci Data. 2020 Oct 8;7(1):345
pubmed: 33033256
Lancet Child Adolesc Health. 2021 Jun;5(6):417-427
pubmed: 33740430
Lancet Microbe. 2021 Jun;2(6):e240-e249
pubmed: 33778792
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Euro Surveill. 2020 Dec;25(49):
pubmed: 33303064
Commun Dis Intell (2018). 2020 Jun 5;44:
pubmed: 32517645
Lancet Infect Dis. 2020 Aug;20(8):911-919
pubmed: 32353347
Nat Commun. 2020 Jul 6;11(1):3436
pubmed: 32632160
J Infect Dis. 2021 Jan 4;223(1):10-14
pubmed: 33009908
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Lancet Glob Health. 2021 May;9(5):e598-e609
pubmed: 33705690
Med J Aust. 2021 Mar;214(4):179-185
pubmed: 33538019
Commun Dis Intell (2018). 2020 Nov 16;44:
pubmed: 33326744
Commun Dis Intell (2018). 2021 Jun 21;45:
pubmed: 34148535
Open Forum Infect Dis. 2020 Aug 27;7(9):ofaa387
pubmed: 32989419